From: The role of protein inhibitor of activated STAT3 and miRNA-18a expressions in breast cancer
Variables | Patients (n = 25) | (%) |
---|---|---|
Age (years) | ||
> 50 | 13 | 52 |
≤ 50 | 12 | 48 |
Focality | ||
Unifocal | 23 | 92 |
Multifocal | 2 | 8 |
Tumor size | ||
< 2 cm | 14 | 56 |
≥ 2 cm | 11 | 44 |
Histopathological type | ||
IDC | 20 | 80 |
ILC | 1 | 4 |
DCIS | 4 | 16 |
Pathological grade | ||
GI | 4 | 16 |
GII | 15 | 60 |
GIII | 6 | 24 |
Lymphovascular invasion | ||
Negative | 3 | 12 |
Positive | 22 | 88 |
LN metastasis | ||
No | 12 | 48 |
Yes | 13 | 52 |
TNM stage | ||
IA | 7 | 28 |
IIA + IIB | 13 | 52 |
III | 5 | 20 |
ER | ||
Positive | 19 | 76 |
Negative | 6 | 24 |
PR | ||
Positive | 19 | 76 |
Negative | 6 | 24 |
HER2 | ||
Positive | 20 | 80 |
Negative | 5 | 20 |
Molecular type | ||
Luminal A | 5 | 20 |
Luminal B | 14 | 56 |
HER2 enriched | 6 | 24 |